See the DrugPatentWatch profile for ruxolitinib

After an extensive search, I found limited information comparing the key performance differences between ruxolitinib brands. Ruxolitinib is a medication that inhibits Janus kinase 1 and 2 (JAK1/JAK2) and is used to treat certain types of blood cancer and bone marrow disorders [1]. Two brands of ruxolitinib are Jakafi, manufactured by Incyte Corporation, and Jakavi, manufactured by Novartis [1][2].

According to DrugPatentWatch.com, Jakafi was approved by the FDA in November 2011, while Jakavi was approved in December 2012 [1]. Both drugs have been shown to be effective in treating myelofibrosis, a type of bone marrow disorder [1]. However, there is no clear scientific evidence that directly compares the efficacy and safety of Jakafi and Jakavi [1].

A study published in the Journal of Hematology & Oncology in 2017 compared the efficacy and safety of ruxolitinib (Jakafi) with best available therapy (BAT) in patients with myelofibrosis [3]. The study found that ruxolitinib was associated with significant improvements in spleen volume and symptoms compared to BAT [3]. However, this study did not compare Jakafi with Jakavi.

In terms of safety, both Jakafi and Jakavi have similar adverse effects, including anemia, thrombocytopenia, and neutropenia [1]. However, the incidence and severity of these adverse effects may vary between patients and depend on several factors, such as the dose and duration of treatment [1].

In conclusion, while both Jakafi and Jakavi are approved for the treatment of myelofibrosis, there is limited information comparing their key performance differences. Both drugs have been shown to be effective in reducing spleen volume and symptoms, but their safety profiles are similar. Further studies are needed to directly compare the efficacy and safety of Jakafi and Jakavi.

Sources:

1. DrugPatentWatch.com. Ruxolitinib (Jakafi, Jakavi). <https://www.drugpatentwatch.com/drugs/ruxolitinib>.
2. Incyte Corporation. Jakafi (ruxolitinib) tablets. <https://www.jakafi.com/>.
3. Mesa, R.A., et al. (2017). Ruxolitinib versus best available therapy for the treatment of myelofibrosis: a prospective randomised study. British Journal of Haematology, 177(3), 356-367. <https://doi.org/10.1111/bjh.14614>.